Amneal Pharma ( (AMRX) ) has released its Q3 earnings. Here is a breakdown of the information Amneal Pharma presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 290 pharmaceutical products, focusing on affordable medicines and specialty branded pharmaceuticals, primarily in the United States.
Amneal Pharmaceuticals reported strong financial results for the third quarter of 2025, with net revenue reaching $785 million, marking a 12% increase from the previous year. The company also updated its full-year guidance, reflecting confidence in its diversified business model and strategic growth initiatives.
Key highlights from the earnings report include a net income of $2 million, a significant improvement from a net loss in the same quarter of the previous year. The company’s adjusted EBITDA was $160 million, and adjusted diluted earnings per share increased to $0.17. The Specialty segment saw an 8% revenue increase, driven by products like CREXONT® and UNITHROID®, while the Affordable Medicines segment also grew by 8%, supported by new product launches and complex product approvals.
Amneal’s updated guidance for 2025 projects net revenue between $3.0 billion and $3.1 billion, with adjusted EBITDA expected to range from $675 million to $685 million. The company anticipates adjusted diluted EPS to be between $0.75 and $0.80, reflecting an upward revision from prior estimates.
Looking ahead, Amneal’s management remains optimistic about the company’s growth trajectory, supported by recent product launches and a strong pipeline. The company is poised to enter 2026 with momentum, driven by its strategic focus on specialty pharmaceuticals and affordable medicines.